文献速递关节外科创伤骨科

口服Xa因子抑制剂用于髋膝关节置换术后血栓栓塞与出血事件的IV期研究

A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
PubMed 文献 · J Arthroplasty · 2016-10-04

这项前瞻性、观察性、非干预性IV期研究纳入3914例连续接受全关节置换术的患者,术后第1天起口服利伐沙班10 mg每日一次、持续15天。3个月症状性深静脉血栓发生率为0.5%(n=18),症状性肺栓塞发生率为0.7%(n=28),预防期间大出血率为0.1%,5%的患者接受输血,无死亡归因于血栓栓塞事件。

要点

  • 3个月症状性深静脉血栓发生率0.5%(n=18),仅1例发生在术后7天内。
  • 3个月症状性肺栓塞发生率0.7%(n=28),其中13例(46%)发生在术后7天内。
  • 预防期间大出血率0.1%,5%的患者接受输血,无死亡归因于血栓栓塞事件。

核心结论

  • 这项前瞻性、观察性IV期研究表明,利伐沙班在所述真实世界环境中似乎可保护患者免于症状性肺栓塞,且未伴随大出血事件。

研究设计与样本

  • 前瞻性、观察性、非干预性IV期研究,纳入2010年6月至2012年12月期间3914例连续接受全关节置换术的患者。
  • 患者术后第1天起口服利伐沙班10 mg每日一次,持续15天;术后6周门诊随访,12周电话联系。
  • 主要结局为症状性静脉血栓栓塞;次要结局包括出血事件、输血需求和死亡。

主要发现

  • 3个月症状性深静脉血栓发生率为0.5%(n=18),仅1例深静脉血栓事件发生在术后7天内。
  • 3个月症状性肺栓塞发生率为0.7%(n=28),其中13例肺栓塞(46%)发生在术后7天内。
  • 预防期间大出血率为0.1%;仅5%的患者接受输血;无死亡归因于血栓栓塞事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple randomized controlled trials have documented the effectiveness of rivaroxaban in the prevention of venous thromboembolism up to 1-month following total joint arthroplasty. However, the effectiveness and safety of rivaroxaban in the real-world setting, outside of the strict protocols used by randomized clinical trials, are unknown. METHODS: This was a prospective, observational, noninterventional, phase IV study of 3914 consecutive patients who underwent total joint arthroplasty from June 2010 to December 2012. Patients were treated with rivaroxaban 10 mg by mouth daily starting postoperative day 1 and continued for 15 days. Participants were followed up in clinic at 6 weeks and contacted by telephone at 12 weeks. The primary outcome of interest was symptomatic venous thromboembolism; secondary outcomes included bleeding events, transfusion requirements, and death. RESULTS: The incidence of symptomatic deep venous thrombosis at 3 months was 0.5% (n = 18). Only 1 deep venous thrombosis event occurred within 7 days of surgery. The incidence of symptomatic pulmonary embolism (PE) at 3 months was 0.7% (n = 28). Thirteen PEs (46%) occurred within 7 days of surgery. The rate of major bleeding while on prophylaxis was 0.1%. Only 5% of patients received a blood transfusion. No deaths were attributed to thromboembolic events. CONCLUSION: This prospective, observational, phase IV study demonstrates that rivaroxaban appears to protect patients against symptomatic PE and is not associated with major bleeding events when used in a real-world setting as described.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Gomez D, Razmjou H, Donovan A, et al. A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor. J Arthroplasty. 2016. PMID: 27843040. doi:10.1016/j.arth.2016.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。